High rate of clinical complete response to weekly outpatient chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin

2000 ◽  
Vol 29 (3) ◽  
pp. 232-234
Author(s):  
J. C. Lin ◽  
J. S. Jan ◽  
C. Y. Hsu ◽  
D. Y. K. Wong
Keyword(s):  
Complete Response ◽  
Oral Carcinoma ◽  
High Rate ◽  
Clinical Complete Response ◽  
Outpatient Chemotherapy

A case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for advanced rectal cancer

2020 ◽  
Vol 13 (5) ◽  
pp. 782-787 ◽  
Author(s):  
Yasuyuki Nakamura ◽  
Fumikazu Koyama ◽  
Kohei Morita ◽  
Hiroyuki Kuge ◽  
Chiho Ohbayashi ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Rectal Adenoma ◽  
Clinical Complete Response

Diagnosis of Clinical Complete Response by Probe-Based Confocal Laser Endomicroscopy (pCLE) After Chemoradiation for Advanced Rectal Cancer

2021 ◽  
Vol 25 (2) ◽  
pp. 357-368
Author(s):  
Adriana Vaz Safatle-Ribeiro ◽  
Carlos Frederico Sparapan Marques ◽  
Clelma Pires ◽  
Lívia Arraes ◽  
Elisa Ryoka Baba ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Confocal Laser Endomicroscopy ◽  
Confocal Laser ◽  
Clinical Complete Response

scholarly journals INNV-17. NEXT GENERATION SEQUENCING IMPACTS OUTCOMES IN RECURRENT PRIMARY GLIOBLASTOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii120-ii120
Author(s):  
Daniel Zeitouni ◽  
Michael Catalino ◽  
Jordan Wise ◽  
Kathryn Pietrosimone ◽  
Sean McCabe ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Cox Model ◽  
Objective Response ◽  
Complete Response ◽  
High Rate ◽  
Next Generation ◽  
Disease Response ◽  
Primary Glioblastoma ◽  
Generation Sequencing ◽  
Recurrent Gbm

Abstract BACKGROUND GBM is driven by various genomic alterations. Next generation sequencing (NGS) may reveal targetable alterations. The goal of this study was to describe how NGS can inform targeted therapy (TT) selection. METHODS The medical records of patients (pts) with GBM from 2017–2019 were reviewed. Pts with actionable mutations were included in the analysis. At first progression (PD1), two cohorts of pts were defined: cohort A received TT, while cohort B received physician’s choice chemotherapy (PCC). Regression analyses were used to determine OS and PFS between cohorts. A stratified cox model was utilized to assess the effect of TT, where KPS level (low vs high) was utilized as a stratification factor. A heat map was generated describing the landscape of mutations. Disease response in cohort A was graded per RANO criteria. RESULTS There were 38 GBM pts with actionable alterations. Cohort A had 15 (39%) pts and cohort B had 23 (61%) pts. Of the 26 common alterations, 11 (42%) were deemed actionable. Pts with higher KPS were more likely to receive TT. Pts with a KPS ≥ 70 had a longer PFS while on TT. Although not well powered, pts in cohort A had a longer median OS relative to cohort B (HR 0.37 CI 0.10–1.38). The objective response rate (ORR) was 93%, with afatinib and cabozantinib resulting in complete response, one pt had progressive disease while on TT. CONCLUSION NGS for recurrent GBM yields a high rate of actionable alterations. Pts that go on TT are often younger and with higher KPS. This likely plays into their improved survival; however, it is notable that the high ORR reflects the value of NGS in deciding on TT to match alterations that are likely to respond. In conclusion, patient selection and availability of NGS impacts outcomes in recurrent GBM.

Sign in / Sign up

Export Citation Format

Share Document